Last reviewed · How we verify
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL
At a glance
| Generic name | DA-EPOCH-R for DLBCL, PTLD, AND PMBCL |
|---|---|
| Also known as | DA-EPOCH-R |
| Sponsor | Baylor College of Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: